A multicenter, single arm, open-label trial to evaluate efficacy and safety of oral, twice daily iptacopan in adult PNH patients who have Hb≥10 g/dL in response to anti-C5 antibody and switch to iptacopan

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502148-10-00

Acronym

CLNP023C12303

Enrollment

Registered

2023-09-19

Start date

2023-10-10

Completion date

2024-10-17

Last updated

2024-06-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Brief summary

Measuring change in hemoglobin levels before start of iptacopan treatment and mean of hemoglobin levels at Day 126 and Day 168

Detailed description

Measuring change in hemoglobin levels before start of iptacopan treatment and mean of hemoglobin levels at Day 126 and Day 168

Interventions

DRUGIPTACOPAN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Measuring change in hemoglobin levels before start of iptacopan treatment and mean of hemoglobin levels at Day 126 and Day 168	—

Secondary

Measure	Time frame
Measuring change in hemoglobin levels before start of iptacopan treatment and mean of hemoglobin levels at Day 126 and Day 168	—

Countries

France, Germany, Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026